Galantamine and Alzheimer’s; Fork Sign Landmark; Instagram in Neurology Education

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer’s dementia, but no evidence supported its use in people with mild cognitive impairment. (Cochrane Database of Systematic Reviews)

Researchers point to the fork sign as a landmark for identifying central sulcus region structures on sagittal MRI images, including the motor hand area. (Brain Communications)

A small study suggested transcranial direct current stimulation may benefit some Parkinson’s patients but could be harmful to others. (npj Parkinson’s Disease)

Researchers identified eight alternative and off-label treatments that target at least one of the underlying mechanisms in amyotrophic lateral sclerosis (ALS). (Annals of Neurology)

Dementia-related stigma is still pervasive, Lancet Neurology editors maintained.

Accelerated brain atrophy was linked with progression to mild cognitive impairment. (JAMA Network Open)

How should clinicians manage comatose patients with epileptiform abnormalities after cardiac arrest? (JAMA Neurology)

Instagram could help further education in neurology and neuroscience, a researcher argued. (Neurology: Education)

Berislav Zlokovic, MD, PhD, a prominent Alzheimer’s and stroke researcher at the University of Southern California who faced scrutiny for possible misconduct, is on an indefinite leave of absence. (Science)

A case report assessed the effect of continuous exposure to ofatumumab (Kesimpta) during pregnancy in a patient with multiple sclerosis. (Neurology Clinical Practice)

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Please enable JavaScript to view the

comments powered by Disqus.